The Buy rating and maintained $5 price target from HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Aquestive Therapeutics. This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a potential short-term increase in the stock price.